
Overview
Ipsen Poland operates in the biopharmaceutical industry, focusing on oncology, rare diseases and neuroscience. The company develops medicines for patients with unmet medical needs; products named in the excerpt include Dysport and IQIRVO.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $660,709 | |
| Profit allocation | Retained in reserve capital | |
| Planned capital expenditure (next year) | $492,215 | |
| Foreign sales | 15.03% of revenue ($14,131,112) | |
| Revenue structure | usługi promocyjne/reklamowe | |
| Receivables write-downs | $14,647 |
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 410 days for 2020). All were audited by a statutory auditor.
- 202516/07/2026
- 202430/06/2025
- 202308/07/2024
- 202211/07/2023
- 202129/11/2022
- 202029/11/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Characterizing the patient experience: The role of patient‑reported outcomes
Biological endpoints are essential, but on their own, they cannot tell the full story. To truly understand the value of a treatment and care surrounding it, we must also seek to understand how patients and carers experience it. This is where patient-reported outcomes (PROs) and observer‑reported outcomes (reflecting the perspectives of non-clinical caregivers) are becoming more prominent in clinical research.

A bridge to the field: how real-world data informs rare disease care
As a Field Medical Advisor in Rare Disease, Antonios Letis works at the intersection of data, physicians, and patients. His focus includes cholestatic conditions such as PBC — areas where innovation has shifted what is possible.

Rethinking discovery: how powerful screening tools are redefining the search for new medicines
In medicine discovery, identifying the right biological target has always been a critical and complex step. Today, the rise of powerful screening tools is fundamentally reshaping this process, creating a step-change in how we move from scientific hypotheses to transformative medicines. Advances in high-throughput screening, genomics and AI-driven analytics are enabling scientists to interrogate disease biology at unprecedented scale, bringing forward opportunities that were previously beyond rea

Adult PFIC: Why Some People Spend Years Searching for Answers
PFIC is a group of rare inherited liver conditions that affects the body's ability to transport and circulate bile, which is essential for digesting and absorbing fats, as well as removing waste products.1–5 When bile builds up in the liver , it can damage the liver and cause symptoms such as itching.1

When science advances, understanding must keep pace
We are living in an era of extraordinary scientific progress. We can target diseases in ways that were unimaginable a generation ago, develop increasingly sophisticated medicines and explore entirely new approaches to treatment.

Building more sustainable laboratories with My Green Lab
Science is at the heart of everything we do. It also comes with an environmental footprint, from the energy and water used in laboratories to the chemicals, equipment and materials required to advance our work.
Industry
- Publishing of books, periodicals and other publishing activities, excluding software (58.1)
Offer
- Oncology medicines
- Rare disease medicines
- Neurological medicines
- Therapies
Website technology
- Website
- WordPress
Authorized Representatives
Manner of representation
Each member of the management board has the right to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ipsen Farmaceutica Bv | 198 | $323,581.85 | 99% |
Others | 2 | $3,268.50 | 1% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2005-09-02.
- 44 1840 0007 2212 8250 0800 1819
- 23 1840 0007 2212 8250 0810 1719
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 67,096PLN 67,096 |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Amgensp. z o.o. | $145,068,009.51 | amgen.pl | ||
| Zentiva Polskasp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Angelini Pharma Polskasp. z o.o. | $119,629,315.69 | angelinipharma.pl | ||
| Stada Pharmsp. z o.o. | $98,071,375.86 | walmark.eu | ||
| Olympus Polskasp. z o.o. | $104,605,078.34 | olympus.pl | ||
| Magnapharm Polandsp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Aurovitas Pharma Polskasp. z o.o. | $78,791,948.37 | aurovitas.pl | ||
| Kol-Dentalsp. z o.o. + limited partnership | $77,358,216.52 | koldental.com.pl | ||
| Baxter Polskasp. z o.o. | $70,731,167.55 | baxter.com.pl | ||
| Galderma Polskasp. z o.o. | $67,939,614.13 | galderma.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-09 | Address change (Ul. Chmielna 73, 00-801, Warszawa → Ul. Chmielna 69, 00-801, Warszawa) | |
| 2021-03-11 | Address change (Al. Jana Pawła Ii 29, 00-867, Warszawa → Ul. Chmielna 73, 00-801, Warszawa) | |
| 2019-06-12 | PKD change (Removed: 5 codes; Added: 9 codes) | |
| 2015-02-27 | PKD change (Removed: 12 codes; Added: 5 codes) | |
| 2014-04-07 | Share capital increase (605,000.00 PLN → 1,210,000.00 PLN) |
FAQ
Last updated: 2026-09-09